Joanna Kamińska1, Marek Stopiński2, Krzysztof Mucha3, Anna Jędrzejczak4, Marek Gołębiowski5, Monika A Niewczas6, Leszek Pączek7, Bartosz Foroncewicz8. 1. Department of Internal Diseases and Dialysis Unit, West Hospital of Saint John Paul II, Daleka 11, 05-825 Grodzisk Mazowiecki, Poland. Electronic address: joaniszka@wp.pl. 2. Department of Internal Diseases and Dialysis Unit, West Hospital of Saint John Paul II, Daleka 11, 05-825 Grodzisk Mazowiecki, Poland. Electronic address: interna@szpitalzachodni.pl. 3. Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warszawa, Poland; Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5A, 02-106 Warszawa, Poland. Electronic address: kjmucha@gmail.com. 4. Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warszawa, Poland. Electronic address: anamarie.jedrzejczak@gmail.com. 5. Department of Clinical Radiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warszawa, Poland. Electronic address: marek.golebiowski@wum.edu.pl. 6. Research Division, Joslin Diabetes Center, 1 Joslin Pl, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA. Electronic address: Monika.Niewczas@joslin.harvard.edu. 7. Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warszawa, Poland; Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5A, 02-106 Warszawa, Poland. Electronic address: leszek.paczek@gmail.com. 8. Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warszawa, Poland. Electronic address: bartosz.foroncewicz@wum.edu.pl.
Abstract
INTRODUCTION: Patients with chronic kidney disease (CKD) have a high risk of death mainly due to cardiovascular diseases (CVD). Early risk identification may allow interventions and prevention of fatal events. OBJECTIVES: The study aim was to assess the usefulness of selected CVD biomarkers as predictors of 5-year mortality in patients with different CKD stages. PATIENTS AND METHODS: Study included 57 CKD patients: 38 in stage 5 (ESRD), 19 in stage 3 and 4 (CKD3-4), and 19 healthy controls. Blood samples were obtained once to measure fetuin A, adiponectin, leptin, tumor necrosis factor (TNF), interleukin-6 (IL-6), metalloproteinase-9 (MMP9), intracellular-1 (ICAM1) and vascular-1 (VCAM1) adhesion molecules (ELISA or Luminex platform). Computed tomography was performed to assess the calcium score (CS). Patients were prospectively followed for 5 years to evaluate their all-cause mortality. RESULTS: Serum VCAM1, TNF and IL-6 were significantly higher in more advanced CKD stages. VCAM1 correlated significantly with ICAM1, TNF and IL-6. TNF and IL-6 were also significantly correlated with each other. No significant changes were detected for other markers. IL-6 correlated significantly with CS, age, renal function and CRP. Elevated CS and IL-6 increased over 3 times the 5-year all-cause and cardiovascular mortality risks in patients with CKD or ESRD at baseline. CONCLUSIONS: IL-6 and CS were significantly associated with 5-year risk of all-cause mortality in CKD patients. Our study suggests an involvement of chronic inflammation linked to coronary artery calcification that is likely to contribute to the cardiovascular mortality in patients with impaired renal function.
INTRODUCTION:Patients with chronic kidney disease (CKD) have a high risk of death mainly due to cardiovascular diseases (CVD). Early risk identification may allow interventions and prevention of fatal events. OBJECTIVES: The study aim was to assess the usefulness of selected CVD biomarkers as predictors of 5-year mortality in patients with different CKD stages. PATIENTS AND METHODS: Study included 57 CKDpatients: 38 in stage 5 (ESRD), 19 in stage 3 and 4 (CKD3-4), and 19 healthy controls. Blood samples were obtained once to measure fetuin A, adiponectin, leptin, tumor necrosis factor (TNF), interleukin-6 (IL-6), metalloproteinase-9 (MMP9), intracellular-1 (ICAM1) and vascular-1 (VCAM1) adhesion molecules (ELISA or Luminex platform). Computed tomography was performed to assess the calcium score (CS). Patients were prospectively followed for 5 years to evaluate their all-cause mortality. RESULTS: Serum VCAM1, TNF and IL-6 were significantly higher in more advanced CKD stages. VCAM1 correlated significantly with ICAM1, TNF and IL-6. TNF and IL-6 were also significantly correlated with each other. No significant changes were detected for other markers. IL-6 correlated significantly with CS, age, renal function and CRP. Elevated CS and IL-6 increased over 3 times the 5-year all-cause and cardiovascular mortality risks in patients with CKD or ESRD at baseline. CONCLUSIONS:IL-6 and CS were significantly associated with 5-year risk of all-cause mortality in CKDpatients. Our study suggests an involvement of chronic inflammation linked to coronary artery calcification that is likely to contribute to the cardiovascular mortality in patients with impaired renal function.
Authors: Susana Rocha; Maria João Valente; Susana Coimbra; Cristina Catarino; Petronila Rocha-Pereira; José Gerardo Oliveira; José Madureira; João Carlos Fernandes; Maria do Sameiro-Faria; Vasco Miranda; Luís Belo; Alice Santos-Silva; Elsa Bronze-da-Rocha Journal: Sci Rep Date: 2021-07-20 Impact factor: 4.379
Authors: Luis Fernando Escobar Guzman; Cristian Andres Escobar Guzman; Neuza Helena Moreira Lopes Journal: Cardiol Res Pract Date: 2020-04-14 Impact factor: 1.866
Authors: Joanna Kamińska; Marek Stopiński; Krzysztof Mucha; Michał Pac; Marek Gołębiowski; Monika A Niewczas; Leszek Pączek; Bartosz Foroncewicz Journal: Int J Gen Med Date: 2021-06-09